Mapatumumab

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

Retrieved on: 
Sunday, September 5, 2021
Cancer, Clinical medicine, Medical specialties, Hepatology, Hepatocellular carcinoma, Febrile neutropenia, Mapatumumab

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 05, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer at ILCA.

Key Points: 
  • We are continuing the expansion phase and will update when new data becomes available.
  • Despite the recent advances, we need more and better systemic therapies for liver cancer, said Dr. Bruno Sangro of Clinica Universidad de Navarra.
  • The first results from this cell therapy trial are of great interest since they indicate obvious antitumor activity in some patients.
  • Dr. Bruno Sangro presented data from Cohort 3 and the expansion phase of the ADP-A2AFP Phase 1 trial during an oral presentation today at ILCA.

BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health sciences, Health, BeiGene, Clinical trial, Mapatumumab, Pelareorep, Tislelizumab, the Tislelizumab Clinical Program, BeiGene, TISLELIZUMAB, THE TISLELIZUMAB CLINICAL PROGRAM, BEIGENE

We hope that, with a growing body of clinical evidence, tislelizumab can become a meaningful immunotherapy that can potentially benefit more patients worldwide.

Key Points: 
  • We hope that, with a growing body of clinical evidence, tislelizumab can become a meaningful immunotherapy that can potentially benefit more patients worldwide.
  • In addition, tislelizumab demonstrated a favorable safety profile compared to chemotherapy, with no new safety signals identified.
  • In this pivotal Phase 2 trial, we observed consistent responses across tumor types with tislelizumab and it was generally well tolerated.
  • BeiGene has initiated or completed 17 potentially registration-enabling clinical trials in China and globally, including 13 Phase 3 trials and four pivotal Phase 2 trials.

Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program

Retrieved on: 
Tuesday, March 16, 2021
Clinical medicine, Medical specialties, Medicine, Monoclonal antibodies, Immunology, Biotechnology, Immune system, Mapatumumab, Ipilimumab

ADG126 is a fully-human, antagonistic monoclonal antibody (mAb) targeting a novel epitope of CTLA-4 and is Adagenes lead SAFEbody product candidate.

Key Points: 
  • ADG126 is a fully-human, antagonistic monoclonal antibody (mAb) targeting a novel epitope of CTLA-4 and is Adagenes lead SAFEbody product candidate.
  • Dosing the first patients in our Phase 1 clinical trial of ADG126 is an exciting milestone for the development of our SAFEbody technology platform, said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene.
  • The global Phase 1 open-label, dose-escalation clinical trial is investigating the tolerability and anti-tumor activity of ADG126 in patients with advanced/metastatic tumors in multiple clinical sites in Australia.
  • Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors

Retrieved on: 
Tuesday, February 9, 2021
Cancer treatments, Clinical medicine, Medicine, Clusters of differentiation, Cancer immunotherapy, Antineoplastic drugs, Breakthrough therapy, Pembrolizumab, CD47, Programmed cell death protein 1, Mapatumumab

Under this collaboration, Arch Oncology is expanding its ongoing Phase 1/2 clinical trial to evaluate AO-176, the Companys novel anti-CD47 antibody, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, for the treatment of patients with select solid tumors.

Key Points: 
  • Under this collaboration, Arch Oncology is expanding its ongoing Phase 1/2 clinical trial to evaluate AO-176, the Companys novel anti-CD47 antibody, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, for the treatment of patients with select solid tumors.
  • As a monotherapy, AO-176 demonstrated encouraging safety and evidence of anti-tumor activity in patients with select solid tumors.
  • AO-176 is being evaluated in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and multiple myeloma, both as monotherapy and in combination with standard therapies.
  • In a Phase 1 trial in solid tumors, AO-176 demonstrated encouraging safety and evidence of anti-tumor activity when administered as a single agent.

ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors

Retrieved on: 
Tuesday, November 3, 2020
Biotechnology, General Health, Health, Clinical trials, Oncology, Cancer treatments, Clinical medicine, Drugs, Cancer immunotherapy, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Pembrolizumab, Antibody-drug conjugates, Camidanlumab tesirine, Mapatumumab, Camidanlumab Tesirine (Cami), ADC Therapeutics

The ongoing, multicenter, open-label, dose-escalation and dose-expansion Phase 1b trial is evaluating the safety, tolerability, pharmacokinetics and antitumor activity of Cami as monotherapy or in combination with pembrolizumab in patients with selected advanced solid tumors.

Key Points: 
  • The ongoing, multicenter, open-label, dose-escalation and dose-expansion Phase 1b trial is evaluating the safety, tolerability, pharmacokinetics and antitumor activity of Cami as monotherapy or in combination with pembrolizumab in patients with selected advanced solid tumors.
  • For more information about the Companys Phase 1b clinical trial of Cami in solid tumors, please visit www.clinicaltrials.gov (identifier NCT03621982).
  • Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma (HL) and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

Retrieved on: 
Monday, October 26, 2020
Drugs, Cancer, Clinical medicine, Monoclonal antibodies, Carcinoma, Cytopathology, Lung cancer, Small-cell carcinoma, Mapatumumab, Tigatuzumab

During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.

Key Points: 
  • During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.
  • The phase III clinical trial of sugemalimab in patients with stage IV non-small cell lung cancer has reached its primary endpoint.
  • CStone plans to submit a new drug application to the National Medical Products Administration of China soon.
  • EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society.

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

Retrieved on: 
Monday, October 26, 2020
Drugs, Cancer, Clinical medicine, Monoclonal antibodies, Carcinoma, Cytopathology, Lung cancer, Small-cell carcinoma, Mapatumumab, Tigatuzumab

During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.

Key Points: 
  • During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.
  • The phase III clinical trial of sugemalimab in patients with stage IV non-small cell lung cancer has reached its primary endpoint.
  • CStone plans to submit a new drug application to the National Medical Products Administration of China soon.
  • EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society.

Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors

Retrieved on: 
Monday, October 5, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Cancer, Oncology, Antineoplastic drugs, Monoclonal antibodies, Cancer immunotherapy, CD47, Chemotherapy, Mapatumumab, Novimmune, AO-176, Arch Oncology

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the expansion of AO-176s clinical development into a Phase 1/2 chemotherapy combination trial for patients with select solid tumors.

Key Points: 
  • Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the expansion of AO-176s clinical development into a Phase 1/2 chemotherapy combination trial for patients with select solid tumors.
  • With patient dosing underway with AO-176 in combination with chemotherapy, we are making significant progress developing AO-176 broadly for patients with solid tumors as well as hematologic malignancies.
  • AO-176 is being evaluated in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and multiple myeloma.
  • In a Phase 1 trial in solid tumors, AO-176 demonstrated encouraging safety and evidence of anti-tumor activity when administered as a single agent.

Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific Program

Retrieved on: 
Friday, May 29, 2020
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Organic compounds, Carbonyl compounds, Oxygen compounds, Taxanes, Ketones, Bristol-Myers Squibb, Paclitaxel, RTT, Mapatumumab, Rebastinib, Deciphera Pharmaceuticals

These findings continue to support the potential of TIE-2 inhibition with rebastinib in combination with paclitaxel, including in patients with prior exposure to paclitaxel.

Key Points: 
  • These findings continue to support the potential of TIE-2 inhibition with rebastinib in combination with paclitaxel, including in patients with prior exposure to paclitaxel.
  • The Phase 1b/2 study of rebastinib in combination with paclitaxel is a two-part, open-label, multicenter study assessing the safety, tolerability, anti-tumor activity and pharmacokinetics of rebastinib in patients with advanced or metastatic solid tumors.
  • As of a February 22, 2020 data cutoff date, a total of 21 patients initiated treatment with rebastinib in the Part 2 cohort of endometrial cancer patients.
  • Deciphera, Deciphera Pharmaceuticals, and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

Retrieved on: 
Wednesday, May 13, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medicine, Clinical medicine, Radiation therapy, Prodrugs, Mapatumumab, Neutron capture therapy of cancer, XmAb®20717, Xencor, Inc.

The American Society of Clinical Oncology (ASCO) has published an abstract (e15001) with initial clinical data from the study on its website today.

Key Points: 
  • The American Society of Clinical Oncology (ASCO) has published an abstract (e15001) with initial clinical data from the study on its website today.
  • In our first six dose-escalation cohorts, we observed XmAb20717 to be generally well-tolerated in heavily pretreated patients with advanced solid tumors.
  • Based on these data and to further characterize safety and activity, we opened expansion cohorts in several tumor types at 10 mg/kg.
  • The study is currently enrolling patients at the 15 mg/kg dose level, and a 20 mg/kg dose cohort is planned.